Shire (NSDQ:SHPGY) said it agreed to acquire Pervasis Therapeutics and its endothelial cell technology for an undisclosed amount.
Boston Scientific launches Pluromed’s BackStop kidney stone treatment | Wall Street Beat
Boston Scientific (NYSE:BSX) launched its BackStop kidney stone treatment product in the U.S. and certain international markets this week.
Sanofi snags hydrogel maker Pluromed for an undisclosed amount
French health care giant Sanofi (NYSE:SNY) signed a definitive agreement to acquire hydrogel maker Pluromed for an undisclosed amount.
Sanofi plans to commercialize Woburn, Mass.-based Pluromed’s LeGoo polymer plug, an injectable gel used during surgical procedures in place of a clamp or snare.
FDA approves surgical gel to stop blood flow | Regulatory Roundup
The FDA approved a surgical gel designed to temporarily stop blood flow during procedures.
The water-soluble, low-viscosity gel designed by Woburn, Mass.-based Pluromed forms a plug at body temperature to temporarily stent blood vessels without damaging them.
Pluromed raises $1.1 million in Series C round
Pluromed Inc. raised $1.1 million, nearly a third of its $3.9 million Series C goal, from a group of 16 un-named investors.
The Woburn, Mass.-based company has netted nearly $8.3 million so far, about $2.5 million from its Series A round and $4 million and $741,000 from two Series B tranches, according to filings with the federal Securities and Exchange Commission.
